相关实验视频

Updated: Jul 23, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

基于双机制的营养分区纳米调节器,用于针对抗PD-1耐药瘤的增强免疫疗法

Ruirui Zhang¹, Ruifang Li¹, Lan Zhang¹

¹School of Biological Engineering, Henan University of Technology, Zhengzhou 450001, China.

|July 14, 2023

概括

这项研究引入了一种新的纳米调节器,可以重新分配营养素,使癌细胞饥饿,并促进T细胞. 这种方法增强了抗瘤免疫力,并克服了对抗PD-1等免疫疗法的耐药性.

科学领域:

生物医学工程生物医学工程
癌症生物学癌症生物学
免疫学免疫学免疫学

背景情况:

癌细胞和T细胞竞争营养,创造了一个免疫抑制瘤微环境 (TME).
这种营养竞争阻碍了T细胞的功能,导致对癌症免疫疗法的反应不佳和耐药性.

研究的目的:

开发一种双机制纳米调节器 (DMNPN),调节TME并改善T细胞营养的可用性.
调查DMNPN增强抗瘤免疫力和克服免疫疗法耐药性的潜力.

主要方法:

DMNPN利用电荷逆转可生物降解的半孔性二氧化封装隆尼达胺 (糖解抑制剂) 和向谷氨酸酶的小干扰RNA.
这一策略抑制了瘤细胞的糖解和谷氨酸的吸收,从而重新分配营养.

主要成果:

DMNPN有效地重塑瘤细胞的新陈代谢和营养分离.
它减轻了免疫抑制的TME,增强了T细胞营养的可用性,并增强了抗瘤免疫力.
DMNPN在抑制抗PD-1耐药瘤,预防转移和复发方面表现出有效性.

结论:

双机制营养分离纳米调节器 (DMNPN) 为癌症治疗提供了一个有前途的策略.
这种方法有效地重新平衡瘤微环境,并增强T细胞介导的抗癌反应.
DMNPN显示出克服免疫疗法耐药性和预防瘤进展的潜力.

关键词:

抗PD-1 耐药瘤的治疗方法这是一种免疫抑制的TME.免疫疗法免疫疗法一个纳米调节器.营养分化的营养分离.

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.